Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients

Table 2

Distribution of ER, PR, and HER2 status between the primary tumor and recurrent lesions ().

Biomarkers	Concordance (%)		Discordance (%)		Total discordance (%)
	PL (+)	PL (−)	PL (+)	PL (−)
	RL (+)	RL (−)	RL (−)	RL (+)
ER	27 (40.3%)	22 (32.8%)	8 (11.9%)	10 (14.9%)	18 (26.9%)
PR	11 (16.4%)	30 (44.8%)	17 (25.4%)	9 (13.4%)	26 (38.8%)
HER2	19 (29.7%)	33 (49.3%)	5 (7.5%)	10 (14.9%)	15 (22.4%)

PL: Primary lesions; RL: Recurrent lesions.